Efficacy & Dosing

wilate achieves therapeutic goals for VWD with a balanced ratio of VWF and FVIII1.

EXAMPLE: Mean Plasma Levels After Loading and Maintenance Doses for Minor Hemorrhages in Type 2 and Type 3 VWD1

FVIII:C = Factor VIII procoagulant activity; RCo = ristocetin cofactor; IVR = in vivo recovery. wilate IVR assumed to be 1.9 IU/dL per IU/kg for VWF:RCo, and 2.2 IU/dL for FVIII:C. ≥ 2:1 ratio product IVR assumed to be 2 IU/dL per IU/kg for VWF:RCo, and 2.4 IU/dL for FVIII:C.

  • With wilate, therapeutic plasma levels of both VWF and FVIII are reached and maintained with a 1:1 ratio
  • A product with a ≥2:1 ratio requires higher doses of VWF to achieve a sufficient level of FVIII when trough levels >30% are targeted

 

Effective Control of Major and Minor Bleeding2

  • In prospective clinical trials with 44 VWD patients and 1095 bleeding episodes, wilate resolved bleeds with a mean daily dose of 29 IU/kg
  • Mean number of treatment days to stop bleeding was 1.9

Dosing in Bleeding Episodes Successfully Treated with wilate2

*A “bleeding episode” may involve bleeding at multiple sites in this analysis. The most common bleeding sites were joints, nose bleeds, stomach bleeds, and mouth bleeds.
†Among 70 VWD patients, 45 patients received wilate on-demand treatment for 1,068 bleeding episodes, including 11 pediatric patients (5-16 years of age), treated for 234 bleeding episodes.1

cta circles background
icon-clip-board Created with Sketch.

wilate is also approved for the perioperative management of bleeding in patients with VWD.

Learn More
References
  1. wilate Full Prescribing Information. Hoboken, NJ: Octapharma; rev 2015.
  2. Berntorp E, et al. Haemophilia. 2009;15:122-130.